Cellebrite DI Ltd (CLBT) Q1 2026 Earnings Call Highlights: Strong ARR Growth and Strategic AI ... - Yahoo Finance

Cellebrite DI Ltd (CLBT) Q1 2026 Earnings Call Highlights: Strong ARR Growth and Strategic AI ... GuruFocus News May 14, 2026 4 min read CLBT +1.10% This article first appeared on GuruFocus. ARR (Annual Recurring Revenue): Increased 21% year-over-year to $493 million. Adjusted EBITDA: $30.6 million, up 29% year-over-year. Free Cash Flow Margin: 32% for the trailing 12 months. Revenue: $128.3 million, up 19% in Q1. Gross Margin: 86%, with gross profit increasing 21% to $110.2 million. Net Income: $30.6 million or $0.12 per share on a fully diluted basis. Cash and Investments: $535 million at the end of the first quarter. Headcount: 1,271 employees at the end of March. Q2 ARR Guidance: Expected in the range of $510 million to $513 million. Q2 Revenue Guidance: Anticipated to be between $130 million to $133 million. Q2 Adjusted EBITDA Guidance: Expected to be between $29 million to $31 million. Warning! GuruFocus has detected 2 Warning Sign with CLBT. Is CLBT fairly valued? Test your thesis with our free DCF calculator. Release Date: May 14, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Cellebrite DI Ltd (NASDAQ:CLBT) reported a 21% year-over-year growth in ARR, reaching $493 million. The company delivered an adjusted EBITDA of $30.6 million, marking a 29% increase year-over-year. Cellebrite's free cash flow margin for the trailing 12 months was 32%, demonstrating strong cash generation. The launch of Genesis, a next-gen AI solution, has received positive feedback from over 500 early adopters across 15 countries. Cellebrite achieved FedRAMP high authorization, opening opportunities with US Federal agencies for its cloud offerings. Negative Points The first quarter saw some deals being pushed, affecting the net new ARR, which remained flat year-on-year. There is uncertainty around the pricing strategy for the new AI products, which could impact initial monetization efforts. The company faces challenges in navigating larger deal sizes, particularly in the Federal space, which could delay revenue recognition. Cellebrite's Q1 growth was modest due to seasonality and a small population of expiring contracts. The geopolitical instability, while a tailwind for business, presents operational challenges, particularly in regions like Asia. Q & A Highlights Q: Could it be that some customers are putting additional Cellebrite core investments on hold temporarily due to the introduction of Genesis and other new products? A: Thomas Hogan, CEO: No, we are not seeing that at all. The introduction of AI capabilities like Genesis is seen as an enhancement to our existing offerings, not a replacement. The value chain starts with evidence collection and extraction, and AI helps process the increasing volume of digital evidence efficiently. Story Continues View Comments Terms and Privacy Policy Privacy Dashboard